KRAS and leukoencephalopathy with calcifications and cysts: However, it is important to emphasize that all these genetic alterations were of uncertain significance in our bioinformatic analysis with the Varsome database, with the exception of a G12C mutation in KRAS, which may lead to treatment adaptation, considering the new KRAS inhibitors under investigation [47] and the potential utility of targeted therapies in LCC as proposed by previous research [8].